Medtronic (NYSE: MDT) executive sells 10,420 shares in preplanned trade

What happened

Medtronic plc (NYSE: MDT) executive Michael Marinaro sold 10,420 ordinary shares on 2026-10-15 at $96.00 each, according to the filing. The sale was about $1.00 million and was disclosed in the Form 4 filed on 2026-10-16, giving investors the first read on the trade.

Marinaro is EVP, Pres MedSurg and Americas. The filing says the trade was made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. The form shows the shares were disposed of directly, not through an indirect holding.

After the sale, Marinaro held 105,916 shares. The filing also identifies the securities as ordinary shares, so the report is limited to a direct sale of common equity and the remaining stake.

Key numbers

Metric	Latest	Change	Source
Shares sold	10,420 shares		SEC Form 4
Sale price	$96.00 per share		SEC Form 4
Total sale value	about $1.00 million		SEC Form 4
Shares held after sale	105,916 shares		SEC Form 4
Holding before sale	116,336 shares		Calculated from SEC Form 4
Shares sold as a share of pre-trade holding	about 9.0%		Calculated from SEC Form 4

Read more: Medtronic (MDT) stock analysis and investment case

Why it matters

OptimistFi's case is that Medtronic turns a large installed base of medical devices into predictable revenue and cash. This filing is mixed because the sale was preplanned, which limits the signal. OptimistFi's calculation puts the 10,420 shares at about 9.0% of the holding before the trade, so the trim is not trivial.

The strongest caveat is the Rule 10b5-1 plan, and the filing shows Marinaro still held 105,916 shares after the sale. That keeps the transaction in the category of routine insider selling, not a sign of a break in Medtronic's operating model for a company whose case rests on steady revenue and cash.

This Form 4 changes the picture only at the margin. It shows one officer cutting a disclosed stake, but it does not point to an operational shift in the business itself.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Medtronic's next quarterly report is the next scheduled check on whether the business keeps producing steady cash and revenue. If the report shows those trends still intact, OptimistFi's case is strengthened. A break in that pattern would weaken it.

Until then, a later Form 4 with a different holding level would be the next insider disclosure to compare against this one. The filing leaves Marinaro with 105,916 shares, so the near-term read stays limited to this planned sale.

More from OptimistFi

• MDT stock: the Medtronic thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps